N. Vantongerloo

Transcriptomics of type 1 diabetes progression: a validation study in newly diagnosed patients

T. Suomi, I. Starskaia, O. Rasool, U.U. Kalim et autres

fi, gb, Soudan du Sud, be, us, dk (code pays fourni par la source)

Transcriptomics of type 1 diabetes progression: a validation study in newly diagnosed patients

Tomi Suomi, Inna Starskaia, Omid Rasool, Ubaid Ullah et autres

BACKGROUND: Type 1 diabetes is an autoimmune disease with significant long-term complications. Variability in the decline of insulin secretion after diagnosis complicates both the development of treatments and disease management. We previously reported that gene expression changes within the first year post-diagnosis …

fi, gb, be, dk, de (code pays fourni par la source)

Gene expression signature predicts rate of type 1 diabetes progression

Tomi Suomi, Inna Starskaia, Ubaid Ullah, Omid Rasool et autres

BACKGROUND: Type 1 diabetes is a complex heterogenous autoimmune disease without therapeutic interventions available to prevent or reverse the disease. This study aimed to identify transcriptional changes associated with the disease progression in patients with recent-onset type 1 diabetes. METHODS: Whole-blood samples …

fi, dk, gb, be, us, de (code pays fourni par la source)

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes

David B. Dunger, Sylvaine F. A. Bruggraber, Adrian Mander, M. Loredana Marcovecchio et autres

BACKGROUND: The INNODIA consortium has established a pan-European infrastructure using validated centres to prospectively evaluate clinical data from individuals with newly diagnosed type 1 diabetes combined with centralised collection of clinical samples to determine rates of decline in beta-cell function and identify …

gb, dk, fi, de, be (code pays fourni par la source)